You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the Editor
Pipeline, aneurysms and the FDA
  1. Joshua A Hirsch1,
  2. Ronil Vikesh Chandra2,3,
  3. Thabele M Leslie-Mazwi2,3
  1. 1Department of NeuroInterventional Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
  2. 2Department of Interventional Neuroradiology, Massachusetts General Hospital, Boston, Massachusetts, USA
  3. 3Department of Endovasular Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Joshua A Hirsch, Department of NeuroInterventional Radiology, Massachusetts General Hospital, 55 Fruit Street, Gray 241B, Boston, MA 02114, USA; hirsch{at}snisonline.org

https://doi.org/10.1136/neurintsurg-2012-010326

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We commend Brinjikji et al on their recent article estimating the proportion of intracranial aneurysms likely to be amenable to treatment with the pipeline embolization device (PED).1 Based on aneurysm and parent artery morphology, 47% of their consecutive sample of 200 aneurysms could theoretically be treated by the PED.

    We believe the paper might …

    View Full Text

    Footnotes

    • Linked article 010327.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles